Clear Bagging, White Bagging, and Gold Bagging: The Revenue Cycle Impact Pharmacies Can’t Ignore

Specialty medications are changing the therapeutic landscape for many chronic and complex conditions. They’re also changing how organizations get paid.

Distribution models such as white bagging, brown bagging, clear bagging, and gold bagging are reshaping reimbursement, operations, and financial performance across pharmacies and provider networks. On the surface, these models look like logistics decisions. In reality, they are complex revenue cycle decisions with lasting consequences.

Understanding the difference is essential. Managing the impact is even more important.

The Growing Shift in Specialty Drug Fulfillment

Specialty pharmacies, hospitals, and health systems are under increasing pressure from payors to control specialty drug costs. One way hospitals and health systems are responding is by steering medications through designated specialty pharmacies instead of traditional buy-and-bill models.

That shift has introduced new fulfillment approaches that directly influence who bills, who gets paid, and how care is coordinated and delivered.

At the same time, many health systems and integrated delivery networks (IDNs) are exploring alternative models—like gold bagging—to comply with payor requirements while maintaining operational control and financial stability.

These decisions affect far more than how a medication reaches the patient. They determine:

• Who bills for the drug
• Who bills for the administration of the drug, if injectable or infused
• Who captures reimbursement
• How workflows are coordinated
• How financial performance is measured

And that puts them squarely in the domain of the revenue cycle.

Understanding the Four Models

Although the terms are sometimes used interchangeably, each model represents a distinct approach with different billing and operational implications.

White Bagging: Common, but Operationally Challenging

In a white bagging model, a payor-mandated specialty pharmacy fills a patient-specific prescription and ships it to the provider site (e.g., hospital, clinic, or infusion center) for administration.

Who bills:

• The specialty pharmacy bills the payor, typically under the pharmacy benefit
• The provider bills only for administration and related services under the medical benefit

Key characteristics:

• The drug is owned by the specialty pharmacy
• Providers have limited control over sourcing and inventory
• Significant coordination is required for shipping, timing, and storage

White bagging can help payors manage drug costs and pharmacy-benefit administration and contracting. For specialty pharmacies, it can represent a stable and growing revenue channel.

For administering providers, however, it often introduces complexity:

• Loss of traditional buy-and-bill drug margin
• Increased administrative coordination
• Limited visibility into the total financial picture
• Potential scheduling delays or inventory complications

From a revenue cycle perspective, white bagging fundamentally changes how revenue is recognized and managed.

Brown Bagging: Largely Discouraged

Brown bagging occurs when medication is shipped directly to the patient, who then transports it to the provider for administration.

While still referenced in policy language, this approach is now widely discouraged due to:

• Patient safety concerns
• Storage and chain-of-custody risks
• Liability issues
• Lack of clinical oversight

Most organizations and payors have moved away from brown bagging in favor of more controlled distribution methods.

Clear Bagging: Health-System Specialty Pharmacy Coordination

Clear bagging refers specifically to a model in which a health system’s own specialty pharmacy dispenses the drug and delivers it internally to the provider for administration. By dispensing medication only when administered, this approach reduces waste and minimizes treatment delays.

In this model:

• The health system retains visibility into sourcing and logistics
• Workflows are better aligned with existing clinical processes
• The internal specialty pharmacy generally bills for the drug under the pharmacy benefit

Who bills:

• The health system specialty pharmacy bills for the medication
• The provider organization bills for administration services when applicable

Clear bagging is often described as a bridge between traditional buy-and-bill and external white bagging, as it keeps distribution and coordination within the health system, while still leveraging pharmacy-benefit billing.

For specialty pharmacies, clear bagging can still support pharmacy-benefit billing while improving coordination with provider partners. For administering providers, it can reduce some of the friction that white bagging creates—though it still alters traditional buy-and-bill revenue streams.

Gold Bagging: Control Through Integration

Gold bagging is a drug distribution model in which high‑cost medications are dispensed through preferred specialty pharmacies, often owned or designated by a health system. This approach allows health systems to retain pharmacy revenue internally while limiting managed care organizations’ (MCOs’) ability to redirect drugs or negotiate alternative pricing. By centralizing dispensing through an in‑house or aligned specialty pharmacy, financial and operational control remains with the provider organization.

Gold bagging offers a strategic alternative for integrated health systems and provider‑owned specialty pharmacies seeking tighter alignment across care delivery.

In this model, the health system oversees the entire process—prescribing, dispensing, and administration—through an integrated care framework. Medications are typically administered at a provider clinic or infusion site within the system, with coordination maintained internally across pharmacy and clinical teams.

Rather than outsourcing fulfillment to an external specialty pharmacy, medications are dispensed by a pharmacy owned or operated within the provider organization. While the drug remains patient‑specific and is delivered to the point of care, the health system retains control over operations, billing, and revenue.

Who Bills:

• The health system’s specialty pharmacy typically bills for the drug, while the provider entity bills for administration services when performed in a clinical setting.
• This model can help protect revenue and maintain clinical and operational alignment. But it only works when supported by strong infrastructure.

Gold bagging programs require:

• Tight coordination between pharmacy and medical billing
• Real-time eligibility and benefit verification
• Accurate split-billing logic
• Patient-specific inventory tracking
• Financial reporting that measures true program performance

Without purpose-built systems, gold bagging can introduce as many challenges as it solves.

Why These Models Matter to Revenue Cycle Performance

From a revenue cycle perspective, bagging models—of all types—create hybrid medical–pharmacy billing scenarios that traditional systems weren’t designed to handle. The impact shows up in several critical areas.

1) Advanced Billing Infrastructure

• Benefit routing
• Claim submission rules
• Modifiers and documentation
• Administration-only billing
• Payor-specific site-of-care policies

Managing those nuances at scale requires automated rules engines and workflows that can adapt in real time.

2) Workflow Automation

Manual coordination between specialty pharmacies, clinics, and billing teams quickly becomes unsustainable. Automation is essential to:

• Route claims correctly
• Trigger eligibility and benefits checks
• Manage prior authorization requirements
• Reduce rework and denials
• Keep clinical teams focused on patient care

Whether an organization is navigating white bagging mandates or implementing gold bagging programs, efficient workflows are the difference between success and operational gridlock.

3) Actionable Analytics

Perhaps the biggest gap in most programs is visibility. Leaders need clear answers to questions like:

• How much revenue is shifting between pharmacy and medical benefits?
• Which payors and drugs are driving the greatest impact?
• Are administration services being reimbursed accurately?
• Is a gold bagging strategy financially viable?
• Where are denials and delays occurring?

Robust analytics turn anecdotal concerns into data-driven decisions—so organizations can respond strategically instead of reactively.

A Strategic Imperative, Not Just a Pharmacy Issue

White bagging, clear bagging, and gold bagging are not niche pharmacy topics. They are part of a broader industry shift toward:

• Converging pharmacy and medical benefits
• More complex reimbursement models
• Heightened payor controls
• Greater pressure on operational efficiency

For specialty pharmacies, these models influence growth strategy and billing workflows. For hospitals and health systems, they shape margins, patient experience, and financial sustainability.

Navigating this landscape successfully requires more than policy changes. It requires technology that connects workflows, automates billing complexity, and delivers financial clarity across both sides of the benefit divide.

Turning Complexity Into Clarity and Confidence

Specialty drug distribution models will continue to evolve. Payor requirements will continue to change. The financial stakes will continue to rise. Organizations that thrive will be the ones with the systems and insights to adapt—quickly, accurately, and at scale.

With the right revenue cycle platform, advanced analytics, and intelligent workflow automation, pharmacies and providers can manage white and clear bagging requirements, implement gold bagging strategies, and protect the resources that fuel patient care.

Ready to strengthen your approach to specialty billing complexity?

Explore how XiFin solutions help organizations unify pharmacy and medical workflows, automate reimbursement processes, and gain real-time financial visibility—so you can navigate change with confidence.